pharma.markets

  • HOME
  • Imprint

cancer

Bayer receives approval for Nubeqa™ in China for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC)

03/02/2021 MaP 0

The Chinese National Medical Products Administration (NMPA) has approved Nubeqa™ (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at […]

Europe’s Beating Cancer Plan: A new EU approach to prevention, treatment and care

03/02/2021 MaP 0

Today, on the eve of the World Cancer Day, the European Commission is presenting Europe’s Beating Cancer Plan – a main priority in the area […]

Bayer and Systems Oncology sign exclusive license agreement on innovative breast cancer treatment approach ERSO™

15/09/2020 MaP 0

Bayer has entered into an exclusive global license agreement with Systems Oncology, LLC, for ERSO™, a compound in pre-clinical development for the treatment of metastatic […]

Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints

20/06/2020 MaP 0

Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary […]

Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response

20/06/2020 MaP 0

…. regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer • IMpassion031 data will be discussed with health authorities globally, […]

FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer

02/06/2020 MaP 0

• Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma • […]

Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer

31/05/2020 MaP 0

• ALEX study is the first global phase III study to show a clinically meaningful benefit in overall survival at five years (62.5% with Alecensa), […]

CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours

31/05/2020 MaP 0

…..and for people with ROS1-positive, advanced non-small cell lung cancer •Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to […]

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

31/05/2020 MaP 0

• Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation […]

FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer

20/05/2020 MaP 0

On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or […]

photo Juan Gaertner/ SciencePhotoLibrary/ Gettyimages

CD4+ Cells in the Fast Lane – Effect of CAR-T Cells in Focus

15/05/2020 MaP 0

CAR-T cells are T lymphocytes, which exist naturally in the human body. They are genetically modified outside the body to equip them with a new […]

Translation

en English
ar Arabiczh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianja Japaneseko Koreanpt Portugueseru Russianes Spanish

Search

Categories

  • Age.related Degeneration
  • Animal health
  • Asthma
  • Cancer
  • COVID-19
  • EIB
  • EU
  • FCPA Investigations
  • FDA
  • Finance
  • Humanitarian Aid
  • Imprint
  • Influenza
  • MS
  • News
  • Research
  • Rheumatology
  • Space Science
  • UN
  • Vaccines

Reports

  • Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
  • Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
  • EU doubles contribution to COVAX to €1 billion to ensure safe and effective vaccines for low and middle-income countries
  • In Vitro Study Published in The New England Journal of Medicine
  • Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®

Archive

  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
  • Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine

    25/02/2021 0
  • Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

    25/02/2021 0
  • Copyright European Commission 2021

    EU doubles contribution to COVAX to €1 billion to ensure safe and effective vaccines for low and middle-income countries

    20/02/2021 0
  • In Vitro Study Published in The New England Journal of Medicine

    17/02/2021 0
  • Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®

    17/02/2021 0
Archives
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
TAGS
affected africa aid biontech cancer commission companies coronavirus covid-19 covid19 crisis economy elpais.com eu europe european fda fight food global guarantee health hygiene italy links medical merck novartis pandemic pfizer production products recommendations region response roche safety scheme sector spain state statistics stats support vaccine

Copyright © 2021 | WordPress Theme by MH Themes